AI enters the cancer patient's agenda: a Zaragoza conference approaches it with "good questions"

By Aragón Digital · November 7, 2026.

The 11th Aragonese Congress of People with Cancer and their Families was held this weekend in Zaragoza with more than 1,100 registered attendees, according to the outlet. The program opened with 34 workshops spread over three hours, many led by associations in the sector, covering exercise, emotions, hereditary genetics, vaccines and end-of-life support.

The morning ended with a panel on precision diagnosis: using medical and scientific tools to tailor treatment to each patient. In the afternoon, a panel on equality in cancer care brought together professionals from Huesca, Teruel and Calatayud, along with a patient who shared her experience.

The keynote lecture was titled «Ay! Ahí está la IA! Cáncer, inteligencia artificial y buenas preguntas» ("Oh! There's the AI! Cancer, artificial intelligence and good questions"). It was given by Sergio Lozares, who holds a PhD in Physics and is a hospital radiophysics specialist at Hospital Universitario Miguel Servet. The report only says that the talk introduced attendees to what AI can do in oncology. It gives no figures, tools or specific conclusions.

Our take. So little technical content was published that no technology can be assessed. What matters is the format: AI is featured at a congress built around patients and families, not at a specialist forum. In our view, the fact that the title talks about «good questions» rather than promises is a good sign of maturity.

In general, public acceptance of AI in healthcare depends on human oversight. Surveys suggest that people trust these tools far more when a professional supervises them than when they work on their own. That a hospital physicist, not a technology vendor, is the one explaining these tools to patients fits with that principle.

There is also a link with precision diagnosis and the panel on territorial equality. In the short term, the risk is that these tools reach large hospitals before Teruel or Calatayud, and that the access gap widens. In the long term, the outcome we argue for is different: personalized, affordable oncology that brings the eradication of many cancers closer. Getting there will require patients to take part in the conversation from now on, and this congress is a small example of that.